Overview Dividends

(IMVT) Immunovant - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US45258J1025

Monoclonal Antibodies, Autoimmune Disease, IMVT-1402, Batoclimab

IMVT EPS (Earnings per Share)

EPS Growth (3Y CAGR): 39.75%
EPS Trend (3Y Correlation): 2.9%

IMVT Revenue

Revenue Growth (3Y CAGR): 0.00%
Revenue Trend (3Y Correlation): 9.6%

Description: IMVT Immunovant November 09, 2025

Immunovant, Inc. (NASDAQ: IMVT) is a clinical-stage biotech that builds monoclonal antibodies targeting B-cell pathways for autoimmune indications. Its lead pipeline includes IMVT-1402, a CD40-targeted antibody being explored in Graves’ disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy (CIDP), cutaneous lupus erythematosus, and Sjögren’s disease, and batoclimab, which is in development for myasthenia gravis, CIDP, and thyroid eye disease. The firm was spun out of Roivant Sciences in 2018 and is headquartered in New York.

Key quantitative signals (as of the most recent 10-Q filing) show a cash runway of roughly $140 million, enough to fund ongoing Phase 2 trials through late 2025, assuming no major cost overruns. The autoimmune market is expanding at a compound annual growth rate of ~ 7 % (2023-2030), driven by aging demographics and increasing willingness to adopt biologics, which underpins demand for novel agents like IMVT-1402. However, the competitive landscape is dense-major players such as Roche (Roche-approved anti-CD40 antibodies) and AbbVie are advancing similar mechanisms, introducing execution risk that could compress market share if Immunovant’s trials do not meet primary endpoints.

For a data-driven, risk-adjusted assessment of IMVT’s upside potential, the ValueRay platform offers a granular model that can help you evaluate the trade-off between clinical milestones and valuation metrics.

IMVT Stock Overview

Market Cap in USD	4,327m
Sub-Industry	Biotechnology
IPO / Inception	2019-06-21

IMVT Stock Ratings

Growth Rating	11.2%
Fundamental	29.6%
Dividend Rating	-
Return 12m vs S&P 500	-31.6%
Analyst Rating	4.64 of 5

IMVT Dividends

Currently no dividends paid

IMVT Growth Ratios

Growth Correlation 3m	85.9%
Growth Correlation 12m	-55.5%
Growth Correlation 5y	36.3%
CAGR 5y	24.58%
CAGR/Max DD 3y (Calmar Ratio)	0.35
CAGR/Mean DD 3y (Pain Ratio)	0.78
Sharpe Ratio 12m	-1.17
Alpha	-33.70
Beta	0.480
Volatility	53.46%
Current Volume	1580.8k
Average Volume 20d	1964.8k
Stop Loss	22.1 (-5.4%)
Signal	0.54

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income (-447.3m TTM) > 0 and > 6% of Revenue (6% = 9600 TTM)

FCFTA -0.63 (>2.0%) and ΔFCFTA -21.84pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 374.3k% (prev 36.3k%; Δ 338.0kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA -0.63 (>3.0%) and CFO -417.1m > Net Income -447.3m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 12.32 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (170.9m) change vs 12m ago 16.97% (target <= -2.0% for YES)

Gross Margin -134.4% (prev 63.27%; Δ -197.6pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 0.03% (prev 0.25%; Δ -0.23pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -60.82 (EBITDA TTM -438.0m / Interest Expense TTM 7.21m) >= 6 (WARN >= 3)

Altman Z'' -32.44

(A) 0.91 = (Total Current Assets 651.8m - Total Current Liabilities 52.9m) / Total Assets 661.4m

(B) -2.06 = Retained Earnings (Balance) -1.36b / Total Assets 661.4m

warn (B) unusual magnitude: -2.06 — check mapping/units

(D) -25.68 = Book Value of Equity -1.36b / Total Liabilities 52.9m

Total Rating: -32.44 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 29.56

1. Piotroski 0.0pt = -5.0

2. FCF Yield -11.20% = -5.0

3. FCF Margin data missing

4. Debt/Equity 0.00 = 2.50

5. Debt/Ebitda 1.37 = 1.19

6. ROIC - WACC (= -91.21)% = -12.50

7. RoE -84.49% = -2.50

8. Rev. Trend 9.64% = 0.72

9. EPS Trend 2.93% = 0.15

What is the price of IMVT shares?

As of November 09, 2025, the stock is trading at USD 23.35 with a total of 1,580,796 shares traded.
Over the past week, the price has changed by -5.39%, over one month by +44.94%, over three months by +48.44% and over the past year by -21.98%.

Is Immunovant a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Immunovant (NASDAQ:IMVT) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 29.56 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of IMVT is around 22.06 USD . This means that IMVT is currently overvalued and has a potential downside of -5.52%.

Is IMVT a buy, sell or hold?

Immunovant has received a consensus analysts rating of 4.64. Therefore, it is recommended to buy IMVT.

Strong Buy: 10
Buy: 3
Hold: 1
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the IMVT price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	38.3	64.2%
Analysts Target Price	38.3	64.2%
ValueRay Target Price	24.4	4.7%

IMVT Fundamental Data Overview November 01, 2025

Market Cap USD = 4.33b (4.33b USD * 1.0 USD.USD)
P/B = 4.7923
Beta = 0.48
Revenue TTM = 160.0k USD
EBIT TTM = -438.4m USD
EBITDA TTM = -438.0m USD
Long Term Debt = 98.0k USD (from capitalLeaseObligations, last fiscal year)
Short Term Debt = 98.0k USD (from shortTermDebt, last fiscal year)
Debt = 98.0k USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -598.9m USD (from netDebt column, last quarter)
Enterprise Value = 3.73b USD (4.33b + Debt 98.0k - CCE 598.9m)
Interest Coverage Ratio = -60.82 (Ebit TTM -438.4m / Interest Expense TTM 7.21m)
FCF Yield = -11.20% (FCF TTM -417.7m / Enterprise Value 3.73b)
FCF Margin = -261.0k% (FCF TTM -417.7m / Revenue TTM 160.0k)
Net Margin = -279.6k% (Net Income TTM -447.3m / Revenue TTM 160.0k)
Gross Margin = -134.4% ((Revenue TTM 160.0k - Cost of Revenue TTM 375.0k) / Revenue TTM)
Gross Margin QoQ = none% (prev 50.0%)
Tobins Q-Ratio = 5.64 (Enterprise Value 3.73b / Total Assets 661.4m)
Interest Expense / Debt = 4148 % (Interest Expense 4.07m / Debt 98.0k)
Taxrate = -0.76% (negative due to tax credits) (913.0k / -119.7m)
NOPAT = -441.7m (EBIT -438.4m * (1 - -0.76%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 12.32 (Total Current Assets 651.8m / Total Current Liabilities 52.9m)
Debt / Equity = 0.00 (Debt 98.0k / totalStockholderEquity, last quarter 608.5m)
Debt / EBITDA = 1.37 (negative EBITDA) (Net Debt -598.9m / EBITDA -438.0m)
Debt / FCF = 1.43 (negative FCF - burning cash) (Net Debt -598.9m / FCF TTM -417.7m)
Total Stockholder Equity = 529.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -67.63% (Net Income -447.3m / Total Assets 661.4m)
RoE = -84.49% (Net Income TTM -447.3m / Total Stockholder Equity 529.4m)
RoCE = -82.79% (EBIT -438.4m / Capital Employed (Equity 529.4m + L.T.Debt 98.0k))
RoIC = -83.43% (negative operating profit) (NOPAT -441.7m / Invested Capital 529.4m)
WACC = 7.78% (E(4.33b)/V(4.33b) * Re(7.78%) + (debt cost/tax rate unavailable))
Discount Rate = 7.78% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 8.73%
Fair Price DCF = unknown (Cash Flow -417.7m)
EPS Correlation: 2.93 | EPS CAGR: 39.75% | SUE: 4.0 | # QB: 1
Revenue Correlation: 9.64 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0

Additional Sources for IMVT Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle